Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZIRCON: Sarilumab in Early Polymyalgia Rheumatica
NCT07286214Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- May 2026
- Primary completion
- Jun 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of sarilumab in polymyalgia rheumatica (PMR), sponsored by Sanofi. Started May 2026; status: recruiting.
02
Drugs
sarilumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT07286214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286214.